Bionovo, a pharmaceutical company, has hired David Boyle as senior vice president (SVP) and chief financial officer (CFO). He will be responsible for directing Bionovo’s financial strategy, accounting, financial planning, business development and investor relations functions. Thomas Chesterman, the company’s former CFO, is to pursue other business interests.
Boyle brings extensive operational and international financial experience to Bionovo. He was previously SVP and CFO of AVI BioPharma, a Washington-based company developing RNA-based therapeutics. Prior to AVI, he was vice president, finance and CFO of XOMA, a California-based leader in the discovery and development of therapeutic antibodies. In addition to his past positions as vice president of finance at Polycom and director of business development at Intel, Boyle has held senior positions in biotechnology and specialty pharmaceutical companies. He was previously at Salix Pharmaceuticals in the US and at Ares Serono Group, both in the US and Switzerland.
The annual BNP Paribas Cash Management University kicked off on Thursday morning with treasury professionals congregating in Paris from across Europe.
APIs may be a solution to MT940 challenges, says Karen Fagan, treasury operation manager, for British television company, ITV.
Kicking off the first day of the Singapore Fintech Festival, issues with cryptocurrencies were addressed by MIT media labs director, Joi Ito, and panels of technology leaders discussed how they’re using data analytics.
Sibos 2017 day two highlights: Brexit and banking, and why ‘data is the new oil’ in financial services
How nation first politics can impact global financial organisations It’s clear that data and regulation are the two key topics that are ... read more